Inventaire - your friends and communities are your best library

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

author

Wei Ding

Charles Erlichman

Tait D Shanafelt

Timothy G. Call

Diane F. Jelinek

Justin C. Boysen

Neil E Kay

Charla R. Secreto

Renee C. Tschumper

Deborah J. Bowen

- 2022

Betsy R LaPlant

published in: American Journal of Hematology

date of publication: 2017-06-01

main subject: lymphocyte, MK-2206, chronic lymphocytic leukemia, rituximab, bendamustine

Cites articles 19

Date

Title

Authors

2015-12-04

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Nancy L Bartlett, Michael Hallek, Sebastian Grosicki, Leylagul Kaynar
2015-03-09

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

Paul M Barr, Ian W. Flinn
2015-04-01

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

John C Byrd, Nyla A Heerema, Kristie A Blum, Jeffrey A Jones, Michael R Grever, Samantha M Jaglowski, Jennifer A Woyach, Leslie A Andritsos, Lynne V Abruzzo, Farrukh T Awan, Gerard Lozanski, Arletta Lozanski, Weiqiang Zhao, Kami Maddocks, Amy S Ruppert, Melanie L Davis, Rose Mantel
2015-01-08

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Hagop Kantarjian, Alessandra Ferrajoli, Zeev Estrov, William G Wierda, Susan O'Brien, Michael J. Keating, Preetesh Jain, Jan A Burger, Danelle F James
2014-03-10

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

John C Byrd, Ian W. Flinn, Stephen E. Spurgeon, Brad S. Kahl, Nina D Wagner-Johnston, Steven Coutre, Langdon L Miller, Brian J Lannutti, Sissy Peterman, Heather E. Webb
2014-05-07

Role of AKT signaling in DNA repair and clinical response to cancer therapy
2013-06-19

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Ian W. Flinn, Nyla A Heerema, Kristie A Blum, Jeffrey A Jones, Jan A Burger, Jeff P Sharman, William G Wierda, Danelle F James, Susan M O'Brien, John C Byrd, Steven Coutre, Weiqiang Zhao, Juthamas Sukbuntherng, Fong Clow
2013-09-20

Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

Charles Erlichman, Shaji K Kumar, Tait D Shanafelt, Timothy G. Call, Neil E Kay, Charla R. Secreto
2011-08-15

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

Clemens-Martin Wendtner, Valentin Goede, Stephan Stilgenbauer, Hartmut Döhner, Michael Hallek, Jasmin Bahlo
2011-12-10

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

Richard Baird
2010-10-12

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

Maryalice Stetler-Stevenson, Stefania Pittaluga, Wyndham H. Wilson
2010-09-07

Modifying akt signaling in B-cell chronic lymphocytic leukemia cells

Tanja N Hartmann
2009-09-08

Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression

Tait D Shanafelt, Timothy G. Call, Clive S Zent, Susan M. Schwager, Justin C. Boysen, Neil E Kay, Asish K. Ghosh, Charla R. Secreto
2009-01-23

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia

Alexander Egle, Ursula Denk
2009-08-27

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
2008-06-15

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Peter Hillmen, Hartmut Döhner, Daniel Catovsky, Michael Hallek, Michael J. Keating, Bruce D. Cheson, Emili Montserrat
2007-10-10

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

Giuseppe Leone, Dimitar Efremov
2005-02-22

Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Giuseppe Leone, Dimitar Efremov
2002-07-12

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta

Ingo Ringshausen

Article - wd:Q33440942

Welcome to Inventaire

the library of your friends and communities

learn more